Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer.

The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.

Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase.

The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014.

Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.